Gemtuzumab Ozogamicin for Relapsed and Refractory Acute Myeloid Leukemia and Myeloid Sarcomas
- 1 September 2004
- journal article
- research article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 45 (9) , 1791-1795
- https://doi.org/10.1080/1042819042000219485
Abstract
(2004). Gemtuzumab Ozogamicin for Relapsed and Refractory Acute Myeloid Leukemia and Myeloid Sarcomas. Leukemia & Lymphoma: Vol. 45, No. 9, pp. 1791-1795.Keywords
This publication has 14 references indexed in Scilit:
- A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemiaBlood, 2003
- Late occurrence of hepatic veno‐occlusive disease following gemtuzumab ozogamicin: successful treatment with defibrotideBritish Journal of Haematology, 2003
- Multidrug resistance protein attenuates gemtuzumab ozogamicin–induced cytotoxicity in acute myeloid leukemia cellsBlood, 2003
- New developments in antibody therapy for acute myeloid leukemiaSeminars in Oncology, 2003
- Differences in CD33 Intensity Between Various Myeloid NeoplasmsAmerican Journal of Clinical Pathology, 2002
- Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin)Leukemia, 2002
- Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapyBlood, 2002
- Efficacy and Safety of Gemtuzumab Ozogamicin in Patients with Poor-prognosis Acute Myeloid LeukemiaLeukemia & Lymphoma, 2002
- Gemtuzumab Ozogamicin, A Potent and Selective Anti-CD33 Antibody−Calicheamicin Conjugate for Treatment of Acute Myeloid LeukemiaBioconjugate Chemistry, 2001
- Calicheamicin γ 1 I and DNA: Molecular Recognition Process Responsible for Site-SpecificityScience, 1989